Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

<p>On this week&#39;s episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State&#39;s life sciences ecosystem while reflecting on her journey from ...

In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

The IRS has changed what must be reported upon filing a research and development (R&D) tax credit claim, and the impact is especially significant for the life sciences industry. The tax form used to ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

Artificial intelligence (AI) is transforming pharmacovigilance by enabling faster, more accurate detection of adverse drug reactions (ADRs), enhancing predictive modeling, and streamlining regulatory ...